Scientists test new cancer Pill's safety with common drugs
NCT ID NCT07372625
Summary
This early-stage study aims to understand how a new oral cancer drug, rezatapopt, interacts with four common medications (metformin, rosuvastatin, repaglinide, and midazolam). It will enroll about 14 adults with advanced solid tumors that have a specific genetic mutation called TP53 Y220C. The main goal is to see if taking rezatapopt changes how the body processes these other drugs and to check the safety of the combinations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
Contact Email: •••••@•••••
-
HealthOne Denver
RECRUITINGDenver, Colorado, 80237, United States
Contact Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
-
SCRI at Mary Crowley
RECRUITINGDallas, Texas, 75230, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.